medigraphic.com
ISSN 1561-302X (Print)

2020, Number 1

<< Back Next >>

Rev cubana med 2020; 59 (1)

Circulating immunocomplexes in systemic erythematous lupus

Kokuin E, Milian OY, Tamargo BTO, Chico CA, Estevez TM, Andux VJL

Language: Spanish
References: 39
Page: 1-15
PDF size: 389.50 Kb.


ABSTRACT

Introduction: Biomarkers are essential in the diagnosis and prognosis of systemic erythematous lupus in which clinical manifestations are extremely complex and heterogeneous.
Objective: To determine the clinical value of circulating immunocomplexes in patients with systemic erythematous lupus.
Methods: Serum levels of C1q-binding immunocomplexes and anti-double-stranded deoxyribonucleic acid (anti-dsDNA), anti-nucleosome (anti-Nuc) and anti-ribosomal proteins (anti-RibP) were determined by enzyme-linked immunosorbent assay (ELISA) in 93 patients diagnosed with systemic lupus erythematosus. Nonparametric tests were used to test the association between immunocomplexes and auto-antibodies. The frequency of lupus nephritis in the circulating immunocomplex positive and negative patient groups was compared using Chi square.
Results: Immunocomplexes were found in 24 (25.8%) patients with systemic lupus erythematosus. The patients with the highest immunocomplex titers were positive for the three autoantibodies used (p = 0.044). A direct correlation was found between the levels of anti-RibP and immunocomplexes (Rho = 0.303, p = 0.003) and between anti-dsDNA and anti-Nuc (Rho = 0.449, p = 0.001). Lupus nephritis occurred in 58.3% of immunocomplex patients, and 31.9% immunocomplex negative patients (p = 0.213).
Conclusions: Circulating immunocomplexes characterized a smaller fraction of patients with systemic lupus erythematosus. Their presence was not associated with anti-dsDNA antibodies or lupus nephritis.


REFERENCES

  1. Koffler D, Agnello V, Thoburn R, Kunkel HG. Systemic lupus erythematosus: prototype of immune complex nephritis in man. J Exp Med. 1971;134:169-79.

  2. Mok CC, Lau CS. Pathogenesis of systemic lupus erythematosus. J Clin Pathol. 2003;56:481-90.

  3. Isenberg DA, Manson JJ, Ehrenstein MR, Rahman A. Fifty years of anti-ds DNA antibodies: are we approaching journey’s end? Rheumatology. 2007;46:1052-6.

  4. Hochberg MC. Updating the American college of rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40(9):1725.

  5. Petri M, Orbai AM, Alarcon GS, Gordon C, Merrill JT, Fortin PR, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64:2677-86.

  6. Romero Díaz J, Isenberg D, Ramsey Goldman R. Measures of adult systemic lupus erythematosus: updated version of British Isles Lupus Assessment Group (BILAG 2004), European Consensus Lupus Activity Measurements (ECLAM), Systemic Lupus Activity Measure, Revised (SLAM-R), Systemic Lupus Activity Questionnaire for Population Studies (SLAQ), Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI- 2K), and Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI). Arthritis Care Res (Hoboken). 2011;63(Suppl 11):37- 46.

  7. Förger F, Matthias T, Oppermann M, Becker H, Helmke K. Clinical significance of antidsDNA antibody isotypes: IgG/IgM ratio of anti-dsDNA antibodies as a prognostic marker for lupus nephritis. Lupus. 2004;14:36-44.

  8. Bizzaro N, Villalta D, Giavarina D, Tozzoli R. Are anti-nucleosome antibodies a better diagnostic marker than anti-dsDNA antibodies for systemic lupus erythematosus? A systematic review and a study of metanalysis. Autoimmun Rev. 2012;12:97-106.

  9. Li T, Prokopec SD, Morrison S, Lou W, Reich H, Gladman D, et al. Anti-nucleosome antibodies outperform traditional biomarkers as longitudinal indicators of disease activity in systemic lupus erythematosus. Rheumatology (Oxford). 2014 Sep 5. pii: keu326. [Epub ahead of print].

  10. Shi ZR, Cao CX, Tan GZ, Wang L. The association of serum anti-ribosomal P antibody with clinical and serological disorders in systemic lupus erythematosus: a systematic review and meta-analysis. Lupus. 2015;24:588-96. https://doi.org/10.1177/0961203314560003

  11. Choi MY, Fitz Patrick RD, Buhler K, Mahler M, Fritzler MJ. A review and metaanalysis of anti-ribosomal P autoantibodies in systemic lupus erythematosus. Autoimmun Rev. 2020;19. doi.org/10.1016/j.autrev.2020.102463

  12. Kokuina E, Estévez M, Gutiérrez A, Ortiz A, Sánchez Y, Pérez D, et al. Anticuerpos anti-nucleosoma frente a marcadores inmunológicos convencionales en el diagnóstico de la actividad del lupus eritematoso sistémico. Rev Cubana Med. 2014;53(4). Disponible en: https://www.revimedicina.sld.cu/index.php/med/login?source=%2Findex.php%2Fmed%2Fe ditor%2Fsubmission%2F1318

  13. Hahn BH, McMahon MA, Wilkinson A, Wallace WD, Daikh DI, Fitzgerald JD, et al. American College of Rheumatology. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res. 2012;64:797- 808. doi 10.1002/acr.21664.

  14. Gauthier VJ, Mannik M. A small proportion of cationic antibodies in immune complexes is sufficient to mediate their deposition in glomeruli. J Immunol. 1990;145:3348-52.

  15. Mannik M, Merrill CE, Stamps LD, Wener MH. Multiple autoantibodies form the glomerular immune deposits in patients with systemic lupus erythematosus. J Rheumatol. 2003;30:1495-504.

  16. Schifferli JA, Taylor RP. Physiological and pathological aspects of circulating immune complexes. Kidney Int. 1989;35:993-1003.

  17. Jarvis JN, Diebold MM, Chadwell MK, Iobidze M, Moore HT. Composition and biological behavior of immune complexes isolated from synovial fluid of patients with juvenile rheumatoid arthritis (JRA). Clin Exp Immunol. 1995;100:514-8.

  18. Sekita K, Doi T, Muso E, Yoshida H, Kanatsu K, Hamashima Y. Correlation of C3d fixing circulating immune complexes with disease activity and clinical parameters in patients with systemic lupus erythematosus. Clin. exp. Immunol. 1984;55:487-94.

  19. Ahlin E, Mathsson L, Eloranta ML, Jonsdottir T, Gunnarsson I, Ronnblom L, et al. Autoantibodies associated with RNA are more enriched than anti-dsDNA antibodies in circulating immune complexes in SLE. Lupus. 2012;21:586-95.

  20. Thanadetsuntorn C, Ngamjanyaporn P, Setthaudom C, Hodge K, Saengpiya N, Pisitkun P . The model of circulating immune complexes and interleukin-6 improves the prediction of disease activity in systemic lupus erythematosus. Scientific Reports. 2018;8:2620. https://doi:10.1038/s41598-018-20947-4

  21. Flores-Mendoza G, Sansón SP, Rodríguez-Castro S, Crispín JC, Rosetti F. Mechanisms of tissue injury in lupus nephritis. Trends Mol Med. 2018;24:364-78. https://doi.org/10.1016/j.molmed.2018.02.003

  22. Zabaleta-Lanz M, Vargas-Arenas RE, Tápanes F, Daboin I, Atahualpa Pinto J, Bianco NE, et al. Silent nephritis in systemic lupus erythematosus. Lupus. 2003;12:26-30.

  23. Hanly JG, O'Keeffe AG, Su L, Urowitz MB, Romero-Diaz J, Gordon C, et al. The frequency and outcome of lupus nephritis: results from an international inception cohort study. Rheumatology. 2016;55:252-62.

  24. Prechl J, Czirják L. The endothelial deprotection hypothesis for lupus pathogenesis: the dual role of C1q as a mediator of clearance and regulator of endothelial permeability. F1000Research. 2015;4:24. https://doi: 10.12688/f1000research.6075.2

  25. Cheung KF, Yung S, Chau MK, Yap DY, Chan KW, Lee CK, et al. Annexin II-binding immunoglobulins in patients with lupus nephritis and their correlation with disease manifestations. Clin Sci (Lond). 2017;131:653-71. https://doi:10.1042/CS20160732

  26. Bruschi M, Galetti M, Sinico RA, Moroni G, Bonanni A, Radice A, et al. Glomerular autoimmune multicomponents of human lupus nephritis in vivo (2): planted antigens. J Am Soc Nephrol. 2015;26:1905-24. https://doi: 10.1681/ASN.2014050493

  27. Fenton K, Fismen S, Hedberg A, Seredkina N, Fenton C, Mortensen ES, et al. AntidsDNA antibodies promote initiation, and acquired loss of renal DNAse1 promotes progression of lupus nephritis in autoimmune (NZBxNZW)F1 mice. PLoS One. 2009;4:8474. https://doi: 10.1371/journal.pone.0008474

  28. Lefkowith, JB, Gilkeson, GS. Nephritogenic autoantibodies in lupus: current concepts and continuing controversies. Arthritis Rheum. 1996;39:894-903.

  29. Mayadas TN, Rosetti F, Ernandez T, Sethi S. Neutrophils: game changers in glomerulonephritis? Trends Mol Med. 2010;16:368-78. doi: https://10.1016/j.molmed.2010.06.002

  30. Yung S, Yap DY, Chan TM. Recent advances in the understanding of renal inflammation and fibrosis in lupus nephritis. F1000 Research. 2017;6(F1000 Faculty Rev):874. https://doi: 10.12688/f1000research.10445.1

  31. Soliman S, Mohan C. Lupus nephritis biomarkers. Clin Immunol. 2017;185:10-20. https://doi.org/10.1016/j.clim.2016.08.001

  32. Mathsson L, Ĺhlin E, Sjöwall C, Skogh T, Rönnelid J. Cytokine induction by circulating immune complexes and signs of in-vivo complement activation in systemic lupus erythematosus are associated with the occurrence of anti-Sjögren’s syndrome A antibodies. Clin Exp Immunol. 2007;147:513-520. https://doi:10.1111/j.1365-2249.2006.03313.x

  33. Ikebe K RC, Gupta RC, Tan EM. Characterization of DNA in polyethylene glycol precipitated immune complexes from sera of patients with systemic lupus erythematosus. Clin Exp Immunol. 1983;54:169-77.

  34. Nezlin R, Alarcón-Segovia D, Shoenfeld Y. Immunochemical determination of DNA in immune complexes present in the circulation of patients with systemic lupus erythematosus. J Autoimmun. 1998;11:489-93. https://doi.org/10.1006/jaut.1998.0231

  35. Abuaf N, Desgruelles C, Moumaris M, Boussa-Khettab F, Rostane H, Bellec E, et al. Detection by flow cytometry of anti-DNA autoantibodies and circulating DNA immune complexes in lupus erythematosus. J Immunol Res. 2019[acceso: 05/12/2019]. https://doi.org/10.1155/2019/6047085

  36. Tron F, Letarte J, Roque Antunes, Barreira MC, Lesavre P. Specific detection of circulating DNA: Anti-DNA immune complexes in human systemic lupus erythematosus sera using murine monoclonal anti-DNA antibody. Clin Exp Immunol. 1982;49:481-87.

  37. Sohrabian A, Ioannis Parodis I, Carlströmer-Berthén N, Frodlund M, Jönsen A, Zickert A, et al. Increased levels of anti-dsDNA antibodies in immune complexes before treatment with belimumab associate with clinical response in patients with systemic lupus erythematosus. Arthritis Res Ther. 2019;21:259. https://doi.org/10.1186/s13075-019-2056-y

  38. Abraham M, Derk CT. Anti‑ribosomal‑P antibodies in lupus nephritis, neuropsychiatric lupus, lupus hepatitis, and Chagas’ disease: promising yet limited in clinical utility. Rheumatol Int. 2015;35:27-33. https://doi 10.1007/s00296-014-3058-3

  39. Hsieh SC, Yu CL. Autoantibody profiling in systemic lupus erythematosus. Curr Biomarker Find. 2013;3:55-56. https://doi:10.2147/CBF. S34496




2020     |     www.medigraphic.com